Omeros (NASDAQ:OMER) Stock Price Up 11.3% – Should You Buy?

Shares of Omeros Corporation (NASDAQ:OMER) traded up 11.3% during trading on Monday . The company traded as high as $9.58 and last traded at $9.6530. Approximately 2,005,229 shares traded hands during trading, an increase of 23% from the average daily volume of 1,633,257 shares. The stock had previously closed at $8.67.

Wall Street Analyst Weigh In

OMER has been the topic of several analyst reports. D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Tuesday, April 21st. Zacks Research raised shares of Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. Wall Street Zen lowered Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, June 7th. Weiss Ratings cut Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 2nd. Finally, HC Wainwright reduced their price target on Omeros from $40.00 to $33.00 and set a “buy” rating on the stock in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $38.00.

Omeros Trading Up 14.6%

The company’s 50 day moving average is $11.90 and its 200 day moving average is $11.86. The company has a market cap of $719.10 million, a PE ratio of 13.98 and a beta of 2.52.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.16. The company had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $4.19 million. Analysts expect that Omeros Corporation will post -0.94 EPS for the current year.

Insider Buying and Selling

In other news, Director Thomas J. Cable sold 7,500 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $11.61, for a total transaction of $87,075.00. Following the transaction, the director owned 35,067 shares in the company, valued at approximately $407,127.87. This trade represents a 17.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OMER. International Assets Investment Management LLC lifted its position in shares of Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 800 shares during the period. Farther Finance Advisors LLC raised its stake in Omeros by 16.5% in the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 1,004 shares in the last quarter. State of Wyoming purchased a new stake in Omeros during the fourth quarter worth $25,000. AQR Capital Management LLC boosted its position in Omeros by 7.2% during the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 1,532 shares in the last quarter. Finally, ProShare Advisors LLC increased its holdings in shares of Omeros by 12.1% in the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 1,637 shares during the period. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.